MedPath

Regadenoson

Generic Name
Regadenoson
Brand Names
Lexiscan, Rapiscan
Drug Type
Small Molecule
Chemical Formula
C15H18N8O5
CAS Number
313348-27-5
Unique Ingredient Identifier
7AXV542LZ4
Background

Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

Indication

Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)

Clinical Trials
Related News

Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia

Phase 1
Completed
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2010-07-13
Last Posted Date
2017-06-23
Lead Sponsor
St. Louis University
Target Recruit Count
46
Registration Number
NCT01161121
Locations
🇺🇸

University of Florida, Jacksonville, Florida, United States

🇺🇸

St. Louis University, Saint Louis, Missouri, United States

Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: Exercise plus Regadenoson (Lexercise)
First Posted Date
2010-04-23
Last Posted Date
2018-10-25
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
43
Registration Number
NCT01109992
Locations
🇺🇸

Brigham and Womens' Hospital, Boston, Massachusetts, United States

Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

Phase 1
Completed
Conditions
Sickle Cell Disease
Interventions
First Posted Date
2010-03-11
Last Posted Date
2014-03-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
39
Registration Number
NCT01085201
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Childrens Hospital Boston, Boston, Massachusetts, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

and more 4 locations

Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing

Not Applicable
Completed
Conditions
Cardiac Function
Interventions
First Posted Date
2009-12-04
Last Posted Date
2022-08-02
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
40
Registration Number
NCT01026012
Locations
🇺🇸

University of MD Cardiology Physicians, Westminster, Maryland, United States

Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging

Not Applicable
Completed
Conditions
Coronary Artery Disease
Myocardial Ischemia
Interventions
Other: Symptom-limited exercise
First Posted Date
2009-11-30
Last Posted Date
2013-03-21
Lead Sponsor
Hartford Hospital
Target Recruit Count
140
Registration Number
NCT01021618
Locations
🇺🇸

Hartford Hospital, Hartford, Connecticut, United States

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)

Phase 4
Completed
Conditions
Coronary Artery Disease
Type 1 Diabetes Mellitus
Interventions
First Posted Date
2009-11-25
Last Posted Date
2015-12-14
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
26
Registration Number
NCT01019486
Locations
🇺🇸

Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States

🇺🇸

University of Colorado Denver, Aurora, Colorado, United States

🇺🇸

University Hospital, the University of Colorado Health Sciences Center, Denver, Colorado, United States

and more 1 locations

Stress Echocardiography Study With Regadenoson

Phase 2
Terminated
Conditions
Heart Disease
Coronary Artery Disease
Interventions
First Posted Date
2009-05-25
Last Posted Date
2014-01-23
Lead Sponsor
Gilead Sciences
Target Recruit Count
22
Registration Number
NCT00907764
Locations
🇬🇧

Northwick Park Hospital, Harrow, United Kingdom

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

Early Phase 1
Completed
Conditions
Ischemic Heart Disease
Interventions
First Posted Date
2009-04-15
Last Posted Date
2012-04-10
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
50
Registration Number
NCT00881218
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

Stress Testing and Cardiac Magnetic Resonance

Phase 4
Completed
Conditions
Coronary Disease
Interventions
First Posted Date
2009-03-30
Last Posted Date
2021-07-12
Lead Sponsor
University of Chicago
Target Recruit Count
20
Registration Number
NCT00871260
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

Phase 4
Completed
Conditions
Kidney Diseases
Coronary Artery Disease
Interventions
Drug: Placebo
First Posted Date
2009-03-18
Last Posted Date
2012-05-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
511
Registration Number
NCT00863707
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy